Diabetes drug meets study goal

09/21/2010 | Bloomberg Businessweek

Adding AstraZeneca and Bristol-Myers Squibb's dapagliflozin to glimepiride, an older diabetes treatment, proved effective in reducing the level of blood sugar in Type 2 diabetics during a late-stage study compared with placebo plus glimepiride. Patients who received dapagliflozin also achieved more weight loss and better oral glucose tolerance after 24 weeks of treatment.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC